Page last updated: 2024-12-05

fomepizole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3406
CHEMBL ID1308
CHEBI ID5141
MeSH IDM0055591

Synonyms (95)

Synonym
AC-4833
BB 0257933
1h-pyrazole, 4-methyl-
brn 0105204
fomepizol [inn-spanish]
einecs 231-445-0
fomepizole [usan:inn]
fomepizolum [inn-latin]
pyrazole, 4-methyl-
NCGC00015646-01
lopac-m-1387
fomepizol
CHEBI:5141 ,
antizol
fomepizolum
4-methyl-1h-pyrazole
4pz ,
7554-65-6
C07837
fomepizole
4-methylpyrazole
DB01213
4-methylpyrazol
D00707
antizol (tn)
fomepizole (jan/usan/inn)
fomepizole, 99%
LOPAC0_000723
NCGC00162231-01
4-mp
STK256626
NCGC00015646-03
smr000059088
MLS001335923
AKOS000265586
CHEMBL1308
nsc-760365
M0774 ,
A9615
EN300-50246
nsc760365
pharmakon1600-01506159
CCG-204808
NCGC00015646-02
nsc 760365
83lcm6l2by ,
antizol-vet
unii-83lcm6l2by
ec 231-445-0
fomepizole [usan:inn:ban]
5-23-05-00031 (beilstein handbook reference)
FT-0626518
NCGC00015646-04
AM20100737
AB00390
S1717
CL3422
fomepizole [jan]
fomepizole [who-dd]
fomepizole [orange book]
fomepizole [inn]
fomepizole [vandf]
fomepizole [usan]
fomepizole [green book]
fomepizole [mart.]
fomepizole [mi]
SY006499
mfcd00005245
4-methyl-pyrazole
4-methyl-1h_pyrazole
4-methyl pyrazole
Q-101886
HY-B0876
AB00918526_07
AB00918526_06
DTXSID3040649 ,
SBI-0050701.P002
HMS3713H14
fomepizole (antizol)
bdbm50226186
Q416410
615557-09-0
HMS3868M13
SDCCGSBI-0050701.P003
NCGC00015646-10
4 methylpyrazole
gtpl11705
A855125
4-methyl-1h-pyrazole;4-methylpyrazole
fomepizole (mart.)
dtxcid1020649
fomepizol (inn-spanish)
fomepizolum (inn-latin)
v03ab34
Z600419582

Research Excerpts

Overview

Fomepizole is an anti-metabolite therapy that is used to diminish the toxicity from methanol or ethylene glycol. It is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose.

ExcerptReferenceRelevance
"Fomepizole is an anti-metabolite therapy that is used to diminish the toxicity from methanol or ethylene glycol. "( Analysis of Fomepizole Elimination in Methanol- and Ethylene Glycol-Poisoned Patients.
Brent, J; McMartin, K, 2022
)
2.54
"Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. "( Fomepizole should not be used more liberally in paracetamol overdose.
Dear, JW, 2023
)
3.8
"Fomepizole is a newer agent with a specific indication for the treatment of ethylene glycol poisoning."( Treatment of ethylene glycol poisoning.
Archie, TE; Ferguson, DR; Piccaro, JC; Scalley, RD; Smart, ML, 2002
)
1.04
"Fomepizole seems to be a safe and valid alternative to ethanol in cases of paediatric methanol poisoning."( Fomepizole as a therapeutic strategy in paediatric methanol poisoning. A case report and review of the literature.
De Brabander, N; De Decker, K; De Weerdt, A; Jorens, PG; Wojciechowski, M, 2005
)
3.21
"Fomepizole is an effective and safe first-line recommended antidote for EG and methanol intoxication. "( Current recommendations for treatment of severe toxic alcohol poisonings.
Baud, FJ; Borron, SW; Mégarbane, B, 2005
)
1.77
"Fomepizole is a recently approved antidote."( [Acute methanol intoxication: physiopathology, prognosis and treatment].
Hantson, PE, 2006
)
1.06
"Fomepizole is an effective alternative to ethanol in the treatment of ethylene glycol poisoning. "( Fomepizole in treatment of uncomplicated ethylene glycol poisoning.
Baud, FJ; Borron, SW; Mégarbane, B, 1999
)
3.19
"Fomepizole is an alcohol dehydrogenase inhibitor used to treat ethylene glycol poisoning in adults, with only one report describing the use of fomepizole in the pediatric population. "( Nystagmus secondary to fomepizole administration in a pediatric patient.
Benitez, JG; Krenzelok, EP; Swanson-Biearman, B, 2000
)
2.06
"Fomepizole is an effective alcohol dehydrogenase inhibitor that decreases production of ethylene glycol metabolites. "( Role of fomepizole in the management of ethylene glycol toxicity.
Druteika, DP; Ensom, MH; Zed, PJ, 2002
)
2.19

Effects

Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor. It may obviate the need for haemodialysis in some, but not all, patients.

ExcerptReferenceRelevance
"Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor that is effective even in the metabolic phase."( Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series.
Link, SL; Osmon, S; Rampon, G; Rumack, BH; Scalzo, AJ, 2022
)
2.89
"Fomepizole has been linked to few adverse effects."( Use of fomepizole (4-methylpyrazole) for acetaminophen poisoning: A scoping review.
Mehrpour, O; Nakhaee, S; Pourbagher-Shahri, AM; Schimmel, J; Shirazi, FM, 2022
)
1.9
"Fomepizole also has the potential to treat intoxication of other substances of abuse by inhibiting ADHs to prevent formation of toxic metabolites."( The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation.
Balesano, A; Di, L; Jordan, S; Shi, SM, 2021
)
1.34
"Fomepizole has few side effects and is easy to use in practice and it may obviate the need for haemodialysis in some, but not all, patients."( Antidotes for poisoning by alcohols that form toxic metabolites.
Hovda, KE; Jacobsen, D; McMartin, K, 2016
)
1.16
"Fomepizole has been utilized with remarkable success for ethylene glycol and methanol poisonings in children and adults. "( Kinetics of fomepizole in pregnant rats.
Gracia, R; Latimer, B; McMartin, KE, 2012
)
2.2
"Fomepizole has clear advantages over ethanol in terms of validated efficacy, predictable pharmacokinetics, ease of administration, and lack of adverse effects, whereas ethanol has clear advantages over fomepizole in terms of long-term clinical experience and acquisition cost."( American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee.
Barceloux, DG; Krenzelok, EP; Olson, K; Watson, W, 1999
)
1.02
"Fomepizole has not been studied adequately in the pediatric population."( Fomepizole treatment of ethylene glycol poisoning in an infant.
Aviles, SR; Baum, CR; Goldstein, CA; Langman, CB; Makar, JK; Oker, EE, 2000
)
2.47
"Fomepizole has been incompletely evaluated in the pediatric population, and the nature and occurrence of adverse events have not been described adequately."( Nystagmus secondary to fomepizole administration in a pediatric patient.
Benitez, JG; Krenzelok, EP; Swanson-Biearman, B, 2000
)
1.34
"Fomepizole appears to have been effective in blocking the toxic metabolism of both methanol and isopropanol and was associated with a favorable outcome."( Treatment of methanol and isopropanol poisoning with intravenous fomepizole.
Astier, A; Baud, FJ; Bekka, R; Bismuth, C; Borron, SW; Sandouk, P, 2001
)
1.27
"Fomepizole has been investigated in 70 patients in open, unblinded studies. "( Role of fomepizole in the management of ethylene glycol toxicity.
Druteika, DP; Ensom, MH; Zed, PJ, 2002
)
2.19

Treatment

Treatment without hemodialysis in massive ethylene glycol ingestion has been rarely reported in the literature. Cats treated with fomepizole received 125 mg/kg IV initially, then 31.25mg/kg at 12, 24, and 36 hours. Treatment blocked formation of HEAA and DGA and kidney toxicity.

ExcerptReferenceRelevance
"The fomepizole treatment protocol (10 mg/kg by i.v. "( Fomepizole (4-methylpyrazole) in fatal methanol poisoning with early CT scan cerebral lesions.
Bonmarchand, G; Callonnec, F; Droy, JM; Girault, C; Leroy, J; Moritz, F; Tamion, F, 1999
)
2.3
"Treatment with fomepizole without hemodialysis in massive ethylene glycol ingestion has been rarely reported in the literature; however, published literature and practice guidelines recommend considering dialysis for ethylene glycol levels >50 mg/dL."( Massive ethylene glycol ingestion treated with fomepizole alone-a viable therapeutic option.
Alhelail, M; Brent, J; Buchanan, JA; Cetaruk, EW; Kulig, K; Palmer, RB; Schaeffer, TH, 2010
)
0.96
"Cats treated with fomepizole received 125 mg/kg IV initially, then 31.25 mg/kg at 12, 24, and 36 hours."( Safety and efficacy of high-dose fomepizole compared with ethanol as therapy for ethylene glycol intoxication in cats.
Connally, HE; Hamar, DW; Thrall, MA, 2010
)
0.97
"Treatment with fomepizole blocked the formation of HEAA and DGA and the development of metabolic acidosis and the kidney and liver toxicity."( Inhibition of metabolism of diethylene glycol prevents target organ toxicity in rats.
Adegboyega, PA; Bartels, M; Besenhofer, LM; Filary, MJ; McLaren, MC; McMartin, KE; Perala, AW, 2010
)
0.7
"Treatment with fomepizole blocked the formation of HEAA and DGA and the kidney toxicity."( Role of tissue metabolite accumulation in the renal toxicity of diethylene glycol.
Bartels, M; Besenhofer, LM; Filary, MJ; Latimer, B; McLaren, MC; McMartin, KE; Perala, AW, 2011
)
0.71

Toxicity

Fomepizole (4-methylpyrazole) is safe and has shown efficacy in preclinical models, human hepatocytes and in volunteers against APAP overdose. HD efficiently clears EG and its toxic metabolites, but it's unclear if multiple doses improve patient outcomes or whether a single dose is sufficient.

ExcerptReferenceRelevance
"The nitrocompounds 3-nitropropanol (NPOH) and 3-nitropropionic acid (NPA) were shown to be equally toxic when injected intraperitoneally into male Wistar rats."( Effect of alcohol and aldehyde dehydrogenase inhibitors on the toxicity of 3-nitropropanol in rats.
Majak, W; Muir, AD; Pass, MA; Yost, GS, 1985
)
0.27
" Both alcohols are metabolised via alcohol dehydrogenase to their toxic metabolites."( Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment.
Jacobsen, D; McMartin, KE,
)
0.13
"The toxic effects of ethanol and acetaldehyde on testosterone biosynthesis were examined in vitro using isolated Leydig cells prepared from adult rat testes."( Inhibition of testosterone production by rat Leydig cells with ethanol and acetaldehyde: prevention of ethanol toxicity with 4-methylpyrazole.
Graham, TJ; Santucci, L; Van Thiel, DH, 1983
)
0.27
"High doses of 4-methylpyrazole (4-MP) could be administered to monkeys in long- and short-term experiments without yielding any general toxicity or any toxic influence on the retinal photoreceptors, the conduction of impulses through the retina or on the activity in the inner nuclear layer detectable by recording the electroretinogram (ERG)."( Normal electroretinogram and no toxicity signs after chronic and acute administration of the alcohol dehydrogenase inhibitor 4-methylpyrazole to the cynomolgus monkey (Macaca fascicularis)--a possible new treatment of methanol poisoning.
Blomstrand, R; Hedström, CG; Ingemansson, SO; Jensen, M, 1984
)
0.27
"When administered four hours after a toxic dose of acetaminophen, 4-methylpyrazole significantly inhibits hepatotoxicity in the rat, as reflected by lower levels of serum transaminases and lesser degrees of hepatic necrosis."( 4-Methylpyrazole blocks acetaminophen hepatotoxicity in the rat.
Baevsky, RH; Brennan, RJ; DelVecchio, JA; Lefevre, R; Mankes, RF; Raccio-Robak, N; Zink, BJ, 1994
)
0.29
" Methanol toxicity initially is not characterized by severe toxic manifestations."( Methanol toxicity. Agency for Toxic Substances and Disease Registry.
, 1993
)
0.29
" Ethanol was toxic to HepG2 E9 cells, which express CYP2E1, but not to HepG2 MV5 cells, which do not express CYP2E1."( Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1.
Cederbaum, AI; Wu, D, 1996
)
0.29
"Neither adverse clinical signs nor clinicopathologic abnormalities were associated with the administration of 4-MP except in 1 dog, which developed tachypnea, gagging, excess salivation, and trembling after the second dose of 4-MP was given."( Safety and efficacy of 4-methylpyrazole for treatment of suspected or confirmed ethylene glycol intoxication in dogs: 107 cases (1983-1995).
Connally, HE; Forney, SD; Grauer, GF; Hamar, DW; Thrall, MA, 1996
)
0.29
"4-MP was a safe and effective treatment for EG intoxication when it was given before sufficient quantities of EG had been metabolized to induce renal failure."( Safety and efficacy of 4-methylpyrazole for treatment of suspected or confirmed ethylene glycol intoxication in dogs: 107 cases (1983-1995).
Connally, HE; Forney, SD; Grauer, GF; Hamar, DW; Thrall, MA, 1996
)
0.29
" These results document the ability of rat P450 2E1 to metabolize NDMA to toxic reactive intermediates and demonstrate that this cell line provides a useful model for studying the mechanisms of metabolism-mediated toxicity and carcinogenesis."( Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.
Hollenberg, PF; Lin, HL; Roberts, ES, 1998
)
0.3
" In conclusion, the administration of 4-MP and/or NAC after 4 h of administering toxic dose of acetaminophen, inhibits hepatotoxicity in rats."( Comparison of the therapeutic efficacy of 4-methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxicity in rats.
Acar, HV; Cankir, Z; Cermik, H; Cinan, U; Danaci, M; Küçükardali, Y; Nalbant, S; Ozkan, S; Top, C, 2002
)
0.31
" Pretreatment with 4-MP increased the Toxic Dose-50 (TD(50)) of 1,4-BD for the righting reflex from 585 mg/kg (95% CI, 484-707 mg/kg) in control mice to 5,550 mg/kg (95% CI, 5,353-5,756 mg/kg) in pretreated mice."( Pretreatment of CD-1 mice with 4-methylpyrazole blocks toxicity from the gamma-hydroxybutyrate precursor, 1,4-butanediol.
Desai, MC; Maher, TJ; Quang, LS; Shannon, MW; Woolf, AD, 2002
)
0.31
"Recent confirmation that the toxic unsaturated aldehyde crotonaldehyde (CA) contributes to protein damage during lipid peroxidation confers interest on the molecular actions of this substance."( Oxidative bioactivation of crotyl alcohol to the toxic endogenous aldehyde crotonaldehyde: association of protein carbonylation with toxicity in mouse hepatocytes.
Burcham, PC; Dunlop, RA; Fontaine, FR; Petersen, DR, 2002
)
0.31
" However, ethanol is frequently co-ingested by those who ingest these more toxic alcohols."( Effects of 4-methylpyrazole on ethanol neurobehavioral toxicity in CD-1 mice.
Maher, T; Páez, AM; Quang, L; Shannon, M, 2004
)
0.32
" Because it is highly toxic and can result in death if not treated appropriately, it is imperative to recognize the signs and symptoms of intoxication."( Ethylene glycol toxicity.
Cox, RD; Phillips, WJ, 2004
)
0.32
" These findings suggest that HepG2 cells were more sensitive to the cytotoxicity of ginkgolic acid than primary rat hepatocytes, and CYP1A and CYP3A could metabolize ginkgolic acid to more toxic compounds."( Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes.
Liu, ZH; Zeng, S, 2009
)
0.35
"1 to 180 mg/kg and reduced the production of a potential toxic metabolite chloroacetaldehyde (CAA) in animal plasma."( Protective effects of fomepizole on 2-chloroethanol toxicity.
Chen, YT; Hung, DZ; Liao, JW, 2010
)
0.68
"Fomepizole is safe when administered to cats in high doses, prevents EG-induced fatal ARF when therapy is instituted within 3 hours of EG ingestion, and is more effective than treatment with EtOH."( Safety and efficacy of high-dose fomepizole compared with ethanol as therapy for ethylene glycol intoxication in cats.
Connally, HE; Hamar, DW; Thrall, MA, 2010
)
2.08
" Although these studies suggest that either metabolite may be involved in producing kidney toxicity, the unexpected renal accumulation of DGA at toxic doses of DEG suggests that it must also be considered a possible toxic metabolite of DEG."( Role of tissue metabolite accumulation in the renal toxicity of diethylene glycol.
Bartels, M; Besenhofer, LM; Filary, MJ; Latimer, B; McLaren, MC; McMartin, KE; Perala, AW, 2011
)
0.37
" HD efficiently clears EG and its toxic metabolites, and it's unclear if multiple doses (MD) of fomepizole improve patient outcomes or whether a single dose (SD) prior to initiation of HD is sufficient."( Single versus continued dosing of fomepizole during hemodialysis in ethylene glycol toxicity.
Marino, RT; Pizon, AF; Sidlak, AM; Van Meerbeke, JP, 2021
)
1.12
"Fomepizole (4-methylpyrazole) is safe and has shown efficacy in preclinical models, human hepatocytes and in volunteers against APAP overdose."( Novel strategies for the treatment of acetaminophen hepatotoxicity.
Akakpo, JY; Jaeschke, H; Ramachandran, A, 2020
)
2
"Methanol toxicity is an important cause of toxic alcohol exposure resulting in morbidity and mortality in both adult and pediatric populations."( Methanol toxicity in a pediatric patient treated with fomepizole and hemodialysis.
Maliakkal, J; McEnery, B; Scalzo, A, 2023
)
1.16

Pharmacokinetics

ExcerptReferenceRelevance
" The half-life of FG in serum was 10."( Comparison of the effects of ethanol and 4-methylpyrazole on the pharmacokinetics and toxicity of ethylene glycol in the dog.
Grauer, GF; Henre, BA; Hjelle, JJ; Thrall, MA, 1987
)
0.27
" The mean peak concentration observed in the 4 adult patients was 18."( Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning.
Detaille, T; Di Fazio, V; Hantson, P; Haufroid, V; König, J; Vanbinst, R; Wallemacq, PE, 2004
)
0.32
" Specifically, the predicted Vss and CL values via interspecies scaling were used in the prediction of series of human intravenous pharmacokinetic parameters, while the simulation of human oral profile was done by the use of absorption rate constant (Ka) from dog following the applicability of human bioavailability value scaled from dog data."( Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles.
Bhamidipati, RK; Chandrasekhar, DV; Jairam, RK; Mallurwar, SR; Mullangi, R; Richter, W; Srinivas, NR; Sulochana, SP; Todmal, U, 2019
)
0.78

Bioavailability

ExcerptReferenceRelevance
" Methanol is well absorbed following inhalation, ingestion or cutaneous exposure."( Methanol toxicity. Agency for Toxic Substances and Disease Registry.
, 1993
)
0.29
" The value of the absorption rate constant in the cyanamide-pretreated group with high acetaldehyde levels was the lowest among the four groups, but there were no significant differences among the remaining groups."( Additional proof of reduction of ethanol absorption from rat intestine in vivo by high acetaldehyde concentrations.
Ameno, K; Ameno, S; Fuke, C; Ijiri, I; Kinoshita, H, 1995
)
0.29
" fomepizole was rapidly absorbed with a bioavailability of approximately 100%."( Oral administration of fomepizole produces similar blood levels as identical intravenous dose.
Forrest, A; Grant, W; Howland, MA; Marraffa, J; McMartin, K; Stork, C, 2008
)
1.57
" Specifically, the predicted Vss and CL values via interspecies scaling were used in the prediction of series of human intravenous pharmacokinetic parameters, while the simulation of human oral profile was done by the use of absorption rate constant (Ka) from dog following the applicability of human bioavailability value scaled from dog data."( Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles.
Bhamidipati, RK; Chandrasekhar, DV; Jairam, RK; Mallurwar, SR; Mullangi, R; Richter, W; Srinivas, NR; Sulochana, SP; Todmal, U, 2019
)
0.78
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The new dosing recommendations for fomepizole and CRRT appeared safe, by maintaining the plasma concentration above the minimum value of 10 µmol/L. The outcomes measured were the preservation of visual acuity, the resolution of metabolic acidosis, the inhibition of formic acid production and death.

ExcerptRelevanceReference
" Because of the apparently unusual kinetics following single dose treatment, thorough multiple dose studies need to be carried out to determine a safe dosage regimen for 4-MP."( Non-linear kinetics of 4-methylpyrazole in healthy human subjects.
Barron, SK; Blomstrand, R; Jacobsen, D; McMartin, KE; Sebastian, CS, 1989
)
0.28
"3 mmol/kg, single dose concomitant with ME or additional ethanol 5 and 10 hr later) reduced the incidence of malformations 60-100%, depending on the dosing regimen."( The relationship of embryotoxicity to disposition of 2-methoxyethanol in mice.
Greene, JA; Sleet, RB; Welsch, F, 1988
)
0.27
" Jugular cannulation allows convenient dosing and sampling of blood, and this technique has been used to study clearance of N-nitrosodimethylamine (NDMA) after intravenous, intraperitoneal and intragastric administration."( The ferret as a model for endogenous synthesis and metabolism of N-nitrosamines.
Fox, JG; Hotaling, LC; Mesina, JE; Tannenbaum, SR; Wishnok, JS, 1987
)
0.27
" Time course experiments and dose-response experiments indicated that an increase in the microsomal oxidation of alcohols could be observed 24 hr after a single treatment with 200 mg/kg body weight of either pyrazole or 4-methylpyrazole, and after 2 or 3 days of treatment with 50 mg/kg of either of these compounds."( Interaction of pyrazole and 4-methylpyrazole with hepatic microsomes: effect on cytochrome P-450 content, microsomal oxidation of alcohols, and binding spectra.
Cederbaum, AI; Feierman, DE,
)
0.13
"48 mmol/kg) followed by oral dosing with ME (2."( Methoxyacetaldehyde, an intermediate metabolite of 2-methoxyethanol, is immunosuppressive in the rat.
Riddle, MM; Smialowicz, RJ; Williams, WC, 1993
)
0.29
" After intraperitoneal dosing of these mutant mice with 4-methylpyrazole, rates of ethanol and methanol metabolism in vivo were decreased significantly, by 41% and 35%, respectively."( 4-Methylpyrazole inhibits fatty acyl coenzyme synthetase and diminishes catalase-dependent alcohol metabolism: has the contribution of alcohol dehydrogenase to alcohol metabolism been previously overestimated?
Bradford, BU; Forman, DT; Thurman, RG, 1993
)
0.29
"For dogs treated with 4-MP, 1 of 2 dosage regimens was usually used: 20 mg/kg of body weight, IV, initially, 15 mg/kg 17 hours later, and 5 mg/kg 25 and 36 hours after the initial dose, or 20 mg/kg, IV, initially, 15 mg/kg 12 and 24 hours later, and 5 mg/kg 36 hours after the initial dose."( Safety and efficacy of 4-methylpyrazole for treatment of suspected or confirmed ethylene glycol intoxication in dogs: 107 cases (1983-1995).
Connally, HE; Forney, SD; Grauer, GF; Hamar, DW; Thrall, MA, 1996
)
0.29
" Exposure of the GM2E1 cells to NDMA for 4 days caused severe decreases in cell viability, as determined by crystal violet uptake, and showed a sigmoidal dose-response curve with a median lethal dose of 17 microM."( Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.
Hollenberg, PF; Lin, HL; Roberts, ES, 1998
)
0.3
" Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol."( The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
Feldwick, MG; Mead, RJ; Menon, KI; Noakes, PS, 2001
)
0.31
" The outcomes measured were the preservation of visual acuity, the resolution of metabolic acidosis, the inhibition of formic acid production, the achievment of therapeutic plasma concentrations of fomepizole with the dosing regimen, residual illness or disability, and death."( Fomepizole for the treatment of methanol poisoning.
Aaron, C; Brent, J; Kulig, K; McMartin, K; Phillips, S, 2001
)
1.94
" Even though 4-MP is characterized by a dose-dependent kinetic profile, under our conditions of dosage and blood sampling, its elimination better fitted a first-order kinetic model."( Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning.
Detaille, T; Di Fazio, V; Hantson, P; Haufroid, V; König, J; Vanbinst, R; Wallemacq, PE, 2004
)
0.32
"D-1 mice were pretreated with 4-MP, with observation of its effect on ethanol dose-response curves."( Effects of 4-methylpyrazole on ethanol neurobehavioral toxicity in CD-1 mice.
Maher, T; Páez, AM; Quang, L; Shannon, M, 2004
)
0.32
" Although supportive care is sufficient in many cases, a specific antidote can significantly reduce morbidity and mortality in a number of poisoning scenarios, and so the pediatric emergency medicine practitioner must be familiar with its indications for use, dosage and administration, and contraindications."( New and novel antidotes in pediatrics.
Calello, DP; Henretig, FM; Osterhoudt, KC, 2006
)
0.33
" Although initial response to all pediatric poisonings begins with basic stabilization, knowledge of specific antidotes, their mechanisms of action, safety profile in pediatrics, and dosing regimens can be life-saving for pediatric victims of nerve gas exposure, acetaminophen toxicity, methanol and ethylene glycol ingestion, and snakebites."( Update on antidotes for pediatric poisoning.
Liebelt, EL; White, ML, 2006
)
0.33
"The patient was treated with the established dosing regimen for fomepizole and the measured S-fomepizole levels throughout the treatment were adequate; the S-methanol elimination also suggests that methanol metabolism was blocked."( Extremely slow formate elimination in severe methanol poisoning: a fatal case report.
Hovda, KE; Jacobsen, D; McMartin, K; Mundal, H; Urdal, P,
)
0.37
" The results showed that EtOH and acetaldehyde decreased ChAT expression at 40 and 240 min after EtOH dosing in the brain."( Ethanol and acetaldehyde: in vivo quantitation and effects on cholinergic function in rat brain.
Ameno, K; Ijiri, I; Ikuo, U; Jamal, M; Kumihashi, M; Wang, W, 2007
)
0.34
" Ethanol (20 mM) reduced the potency of the PPARbeta ligand GW0742, evident by a rightward shift in the GW0742 dose-response curve, whereas for PPARalpha activation by GW7647, ethanol mediated its effects primarily through reducing efficacy as evidenced by a reduction in maximal response."( PPARalpha and PPARbeta are differentially affected by ethanol and the ethanol metabolite acetaldehyde in the MCF-7 breast cancer cell line.
Aung, CS; Cabot, PJ; Monteith, GR; Roberts-Thomson, SJ; Venkata, NG, 2008
)
0.35
" She received fomepizole at dosing corrected for hemodialysis(HD), and bicarbonate via multiple boluses and continuous infusion."( Head CT in patient with metabolic acidosis.
Babu, KM; Boyer, EW; Rosenbaum, CD, 2008
)
0.71
" Other groups were treated with 164mg/kg/d of the alcohol dehydrogenase (ADH) inhibitor 4-methylpyrazole (4-MP) and dosed at 2-3g/kg/d ethanol to maintain similar average urine ethanol concentrations."( The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat.
Badeaux, J; Badger, TM; Blackburn, ML; Korourian, S; Ronis, MJ, 2010
)
0.36
"The limited data available suggest that fomepizole, using the same dosage regimen as that used for adults, is efficacious and well tolerated in pediatric patients."( Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings.
Brent, J, 2010
)
2.07
" Fisher's exact test determined significant differences in the proportion of ethanol and fomepizole-treated cases with medication error and univariate logistic regression identified risk factors associated with harmful dosage errors."( Medication errors associated with the use of ethanol and fomepizole as antidotes for methanol and ethylene glycol poisoning.
Baker, JL; Daws, DE; Dewitt, CR; Erhardt, GD; Kennedy, JR; Lepik, KJ; Levy, AR; Purssell, RA; Sobolev, BG, 2011
)
0.84
" As such, these kinetic evaluations in healthy humans support the current dosing recommendations for fomepizole."( Kinetics and metabolism of fomepizole in healthy humans.
Dies, D; Jacobsen, D; McMartin, KE; Sebastian, CS, 2012
)
0.89
"In cases of ethylene glycol (EG) toxicity requiring hemodialysis (HD), fomepizole is dosed every four hours."( Single versus continued dosing of fomepizole during hemodialysis in ethylene glycol toxicity.
Marino, RT; Pizon, AF; Sidlak, AM; Van Meerbeke, JP, 2021
)
1.13
" We compared patients who received a single dose of fomepizole prior to HD to those who received continued dosing during and after HD."( Single versus continued dosing of fomepizole during hemodialysis in ethylene glycol toxicity.
Marino, RT; Pizon, AF; Sidlak, AM; Van Meerbeke, JP, 2021
)
1.15
"Patients with moderately severe EG toxicity (acidosis and no initial renal dysfunction) treated with a single dose of fomepizole prior to HD had similar outcomes to those receiving continued dosing of fomepizole during or after HD."( Single versus continued dosing of fomepizole during hemodialysis in ethylene glycol toxicity.
Marino, RT; Pizon, AF; Sidlak, AM; Van Meerbeke, JP, 2021
)
1.11
" Our aim was to study whether this new dosing for fomepizole during CRRT gave plasma concentrations above the required 10 µmol/L."( Fomepizole dosing during continuous renal replacement therapy - an observational study.
Foreid, S; Froeyshov, S; Holm, P; Hovda, KE; Jacobsen, D; Kvaerner, C; Lao, YE; Latimer, B; Mataric, M; McMartin, K; Vartdal, T, 2022
)
2.42
" The new dosing recommendations for fomepizole and CRRT appeared safe, by maintaining the plasma concentration above the minimum value of 10 µmol/L."( Fomepizole dosing during continuous renal replacement therapy - an observational study.
Foreid, S; Froeyshov, S; Holm, P; Hovda, KE; Jacobsen, D; Kvaerner, C; Lao, YE; Latimer, B; Mataric, M; McMartin, K; Vartdal, T, 2022
)
2.44
"Plasma concentrations during the repeated dosing confirmed that the recommended dosing schedule, with and without intermittent hemodialysis, maintained therapeutic concentrations throughout the treatments."( Analysis of Fomepizole Elimination in Methanol- and Ethylene Glycol-Poisoned Patients.
Brent, J; McMartin, K, 2022
)
1.1
" The standard oral or intravenous dosing regimen of NAC is highly effective for patients with moderate overdoses who present within 8 h of APAP ingestion."( Comparing N-acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose.
Akakpo, JY; Curry, SC; Jaeschke, H; Ramachandran, A; Rumack, BH, 2022
)
0.72
" Therapy failure was noted mostly when marked acidemia and/or acute kidney injury were present prior to therapy, although there were cases of failed ethanol monotherapy with minimal acidemia (suggesting that ethanol dosing and/or monitoring may not have been optimal)."( Treating ethylene glycol poisoning with alcohol dehydrogenase inhibition, but without extracorporeal treatments: a systematic review.
Beaulieu, J; Ghannoum, M; Gosselin, S; Hoffman, RS; Hovda, KE; Lavergne, V; Lung, D; Megarbane, B; Roberts, DM; Thanacoody, R, 2022
)
0.72
" Other advancements include individualized acetylcysteine dosing regimens for acetaminophen toxicity and carnitine supplementation in valproic acid toxicity."( The Roles of Antidotes in Emergency Situations.
Dart, RC; Kaiser, SK, 2022
)
0.72
" The dosage of antidotes (fomepizole or ethanol) needs to be adjusted during ECTR."( Extracorporeal treatment for ethylene glycol poisoning: systematic review and recommendations from the EXTRIP workgroup.
Bird, S; Ghannoum, M; Gosselin, S; Hassanian-Moghaddam, H; Hoffman, RS; Kallab, S; Lavergne, V; Mégarbane, B; Rif, M; Roberts, DM; Wood, DM, 2023
)
1.21
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antidoteAny protective agent counteracting or neutralizing the action of poisons.
protective agentSynthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.
EC 1.1.1.1 (alcohol dehydrogenase) inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of alcohol dehydrogenase (EC 1.1.1.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
ethanol degradation II416
ethanol degradation I415
ethanolamine utilization1336
mixed acid fermentation3276
superpathway of N-acetylneuraminate degradation3979
pyruvate fermentation to ethanol I1020

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624146
EWS/FLI fusion proteinHomo sapiens (human)Potency0.02940.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency18.88760.035520.977089.1251AID504332
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alcohol dehydrogenase E chainEquus caballus (horse)Ki0.14120.14122.89278.7000AID33855
Alcohol dehydrogenase S chainEquus caballus (horse)Ki0.14120.14122.89278.7000AID33855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alcohol dehydrogenase E chainEquus caballus (horse)Kd0.01300.01300.10650.2000AID1146292
Alcohol dehydrogenase S chainEquus caballus (horse)Kd0.01300.01300.10650.2000AID1146292
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1146292Inhibition of horse liver alcohol dehydrogenase using ethanol as substrate assessed as dissociation constant by spectrophotometric titration in presence of 1 mM NAD+1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
3-Substituted pyrazole derivatives as inhibitors and inactivators of liver alcohol dehydrogenase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID33855Inhibitory activity against horse liver alcohol dehydrogenase (ADH)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID23467Partition coefficient (logP)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (544)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990103 (18.93)18.7374
1990's122 (22.43)18.2507
2000's156 (28.68)29.6817
2010's110 (20.22)24.3611
2020's53 (9.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.53 (24.57)
Research Supply Index6.42 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index120.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (4.09%)5.53%
Reviews55 (9.37%)6.00%
Case Studies92 (15.67%)4.05%
Observational3 (0.51%)0.25%
Other413 (70.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of 4-methylpyrazole on Oxidative Metabolism of Acetaminophen in Healthy Volunteers [NCT03878693]Early Phase 16 participants (Actual)Interventional2018-07-01Completed
Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation [NCT00346853]Phase 110 participants (Actual)Interventional2005-11-30Completed
A Phase IIa, Prospective, Randomized, Blinded, Intra-Subject Controlled, Single Dose, Dose Escalation Study of Antizol® for Mitigation of Acetaldehyde Related Toxicity in Human Subjects With Symptoms of Inborn Altered Ethanol Metabolism With Concomitant E [NCT00661141]Phase 232 participants (Actual)Interventional2008-04-30Completed
"Specified Drug-use Survey of Fomepizole Intravenous Infusion Takeda (All-case Surveillance)" [NCT02415712]143 participants (Actual)Observational2015-01-27Completed
A Randomized Controlled Study to Evaluate the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose [NCT05517668]Phase 240 participants (Anticipated)Interventional2022-09-12Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00661141 (32) [back to overview]Pharmacokinetics (PK) of 4-MP: Maximum Plasma Concentration (Cmax)
NCT00661141 (32) [back to overview]PK of 4-MP: Apparent Clearance (CL/F)
NCT00661141 (32) [back to overview]PK of 4-MP: Apparent Volume of Distribution During Terminal Phase (Vz/F)
NCT00661141 (32) [back to overview]PK of 4-MP: Area Under the Plasma Concentration-Time Curve (AUC), Calculated to the Last Measured Concentration (AUC[0-t])
NCT00661141 (32) [back to overview]PK of 4-MP: AUC, From Time 0 Extrapolated to Infinite Time (AUC[0-∞])
NCT00661141 (32) [back to overview]PK of 4-MP: DN AUC(0-∞)
NCT00661141 (32) [back to overview]PK of 4-MP: DN AUC(0-t)
NCT00661141 (32) [back to overview]PK of 4-MP: Dose-Normalized (DN) Cmax
NCT00661141 (32) [back to overview]PK of 4-MP: Half-Life (T1/2)
NCT00661141 (32) [back to overview]PK of 4-MP: Percentage of AUC0-∞ Obtained by Extrapolation (AUC%Extrap)
NCT00661141 (32) [back to overview]PK of 4-MP: Time to Cmax (Tmax)
NCT00661141 (32) [back to overview]PK of Acetaldehyde: AUC(0-∞)
NCT00661141 (32) [back to overview]PK of Acetaldehyde: AUC(0-t)
NCT00661141 (32) [back to overview]PK of Acetaldehyde: AUC%Extrap
NCT00661141 (32) [back to overview]PK of Acetaldehyde: Cmax
NCT00661141 (32) [back to overview]PK of Acetaldehyde: DN AUC(0-∞)
NCT00661141 (32) [back to overview]PK of Acetaldehyde: DN AUC(0-t)
NCT00661141 (32) [back to overview]PK of Acetaldehyde: DN Cmax
NCT00661141 (32) [back to overview]PK of Acetaldehyde: T1/2
NCT00661141 (32) [back to overview]PK of Acetaldehyde: Tmax
NCT00661141 (32) [back to overview]PK of Ethanol: AUC(0-∞)
NCT00661141 (32) [back to overview]PK of Ethanol: AUC(0-t)
NCT00661141 (32) [back to overview]PK of Ethanol: AUC%Extrap
NCT00661141 (32) [back to overview]PK of Ethanol: CL/F
NCT00661141 (32) [back to overview]PK of Ethanol: Cmax
NCT00661141 (32) [back to overview]PK of Ethanol: DN AUC(0-∞)
NCT00661141 (32) [back to overview]PK of Ethanol: DN AUC(0-t)
NCT00661141 (32) [back to overview]PK of Ethanol: DN Cmax
NCT00661141 (32) [back to overview]PK of Ethanol: T1/2
NCT00661141 (32) [back to overview]PK of Ethanol: Tmax
NCT00661141 (32) [back to overview]PK of Ethanol: Vz/F
NCT00661141 (32) [back to overview]Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation

Pharmacokinetics (PK) of 4-MP: Maximum Plasma Concentration (Cmax)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionng/mL (Mean)
1.0 mg/kg Antizol Followed by Ethanol2386
Ethanol Followed by 1.0 mg/kg Antizol1358
3.0 mg/kg Antizol Followed by Ethanol5605
Ethanol Followed by 3.0 mg/kg Antizol4680
5.0 mg/kg Antizol Followed by Ethanol8623

[back to top]

PK of 4-MP: Apparent Clearance (CL/F)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionL/hr (Mean)
1.0 mg/kg Antizol Followed by Ethanol6.70
Ethanol Followed by 1.0 mg/kg Antizol8.23
3.0 mg/kg Antizol Followed by Ethanol3.15
Ethanol Followed by 3.0 mg/kg Antizol2.99
5.0 mg/kg Antizol Followed by Ethanol2.35

[back to top]

PK of 4-MP: Apparent Volume of Distribution During Terminal Phase (Vz/F)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionLiters (Mean)
1.0 mg/kg Antizol Followed by Ethanol26.3
Ethanol Followed by 1.0 mg/kg Antizol24.7
3.0 mg/kg Antizol Followed by Ethanol24.4
Ethanol Followed by 3.0 mg/kg Antizol24.9
5.0 mg/kg Antizol Followed by Ethanol24.7

[back to top]

PK of 4-MP: Area Under the Plasma Concentration-Time Curve (AUC), Calculated to the Last Measured Concentration (AUC[0-t])

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionng*hr/mL (Mean)
1.0 mg/kg Antizol Followed by Ethanol13804
Ethanol Followed by 1.0 mg/kg Antizol7409
3.0 mg/kg Antizol Followed by Ethanol44942
Ethanol Followed by 3.0 mg/kg Antizol34310
5.0 mg/kg Antizol Followed by Ethanol109298

[back to top]

PK of 4-MP: AUC, From Time 0 Extrapolated to Infinite Time (AUC[0-∞])

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionng*hr/mL (Mean)
1.0 mg/kg Antizol Followed by Ethanol11035
Ethanol Followed by 1.0 mg/kg Antizol7627
3.0 mg/kg Antizol Followed by Ethanol55452
Ethanol Followed by 3.0 mg/kg Antizol57028
5.0 mg/kg Antizol Followed by Ethanol136871

[back to top]

PK of 4-MP: DN AUC(0-∞)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Intervention(ng*hr/mL)/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol149
Ethanol Followed by 1.0 mg/kg Antizol122
3.0 mg/kg Antizol Followed by Ethanol317
Ethanol Followed by 3.0 mg/kg Antizol334
5.0 mg/kg Antizol Followed by Ethanol460

[back to top]

PK of 4-MP: DN AUC(0-t)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Intervention(ng*hr/mL)/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol223
Ethanol Followed by 1.0 mg/kg Antizol103
3.0 mg/kg Antizol Followed by Ethanol231
Ethanol Followed by 3.0 mg/kg Antizol204
5.0 mg/kg Antizol Followed by Ethanol378

[back to top]

PK of 4-MP: Dose-Normalized (DN) Cmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Intervention(ng/mL)/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol38.3
Ethanol Followed by 1.0 mg/kg Antizol18.9
3.0 mg/kg Antizol Followed by Ethanol27.6
Ethanol Followed by 3.0 mg/kg Antizol28.0
5.0 mg/kg Antizol Followed by Ethanol30.2

[back to top]

PK of 4-MP: Half-Life (T1/2)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionhours (Mean)
1.0 mg/kg Antizol Followed by Ethanol2.72
Ethanol Followed by 1.0 mg/kg Antizol3.11
3.0 mg/kg Antizol Followed by Ethanol5.37
Ethanol Followed by 3.0 mg/kg Antizol5.76
5.0 mg/kg Antizol Followed by Ethanol9.26

[back to top]

PK of 4-MP: Percentage of AUC0-∞ Obtained by Extrapolation (AUC%Extrap)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionpercentage (Mean)
1.0 mg/kg Antizol Followed by Ethanol16.8
Ethanol Followed by 1.0 mg/kg Antizol13.0
3.0 mg/kg Antizol Followed by Ethanol3.31
Ethanol Followed by 3.0 mg/kg Antizol4.37
5.0 mg/kg Antizol Followed by Ethanol13.2

[back to top]

PK of 4-MP: Time to Cmax (Tmax)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionhours (Median)
1.0 mg/kg Antizol Followed by Ethanol1.00
Ethanol Followed by 1.0 mg/kg Antizol2.50
3.0 mg/kg Antizol Followed by Ethanol0.667
Ethanol Followed by 3.0 mg/kg Antizol1.48
5.0 mg/kg Antizol Followed by Ethanol1.00

[back to top]

PK of Acetaldehyde: AUC(0-∞)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionµM*hr (Mean)
1.0 mg/kg Antizol Followed by Ethanol234
Ethanol Followed by 1.0 mg/kg Antizol154
3.0 mg/kg Antizol Followed by Ethanol297
Ethanol Followed by 3.0 mg/kg Antizol302
5.0 mg/kg Antizol Followed by Ethanol188
Placebo Followed by Ethanol205
Ethanol Followed by Placebo227

[back to top]

PK of Acetaldehyde: AUC(0-t)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionµM*hr (Mean)
1.0 mg/kg Antizol Followed by Ethanol178
Ethanol Followed by 1.0 mg/kg Antizol118
3.0 mg/kg Antizol Followed by Ethanol155
Ethanol Followed by 3.0 mg/kg Antizol167
5.0 mg/kg Antizol Followed by Ethanol128
Placebo Followed by Ethanol163
Ethanol Followed by Placebo139

[back to top]

PK of Acetaldehyde: AUC%Extrap

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionpercentage (Mean)
1.0 mg/kg Antizol Followed by Ethanol19.0
Ethanol Followed by 1.0 mg/kg Antizol18.8
3.0 mg/kg Antizol Followed by Ethanol13.1
Ethanol Followed by 3.0 mg/kg Antizol9.78
5.0 mg/kg Antizol Followed by Ethanol24.7
Placebo Followed by Ethanol13.7
Ethanol Followed by Placebo14.5

[back to top]

PK of Acetaldehyde: Cmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionµM (Mean)
1.0 mg/kg Antizol Followed by Ethanol59.6
Ethanol Followed by 1.0 mg/kg Antizol37.6
3.0 mg/kg Antizol Followed by Ethanol50.9
Ethanol Followed by 3.0 mg/kg Antizol55.9
5.0 mg/kg Antizol Followed by Ethanol40.0
Placebo Followed by Ethanol60.3
Ethanol Followed by Placebo42.7

[back to top]

PK of Acetaldehyde: DN AUC(0-∞)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionµM*hr/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol0.00682
Ethanol Followed by 1.0 mg/kg Antizol0.00432
3.0 mg/kg Antizol Followed by Ethanol0.00929
Ethanol Followed by 3.0 mg/kg Antizol0.0105
5.0 mg/kg Antizol Followed by Ethanol0.00626
Placebo Followed by Ethanol0.00616
Ethanol Followed by Placebo0.00752

[back to top]

PK of Acetaldehyde: DN AUC(0-t)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionµM*hr/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol0.00547
Ethanol Followed by 1.0 mg/kg Antizol0.00329
3.0 mg/kg Antizol Followed by Ethanol0.00470
Ethanol Followed by 3.0 mg/kg Antizol0.00597
5.0 mg/kg Antizol Followed by Ethanol0.00439
Placebo Followed by Ethanol0.00521
Ethanol Followed by Placebo0.00455

[back to top]

PK of Acetaldehyde: DN Cmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventionµM/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol0.00181
Ethanol Followed by 1.0 mg/kg Antizol0.00104
3.0 mg/kg Antizol Followed by Ethanol0.00157
Ethanol Followed by 3.0 mg/kg Antizol0.00201
5.0 mg/kg Antizol Followed by Ethanol0.00138
Placebo Followed by Ethanol0.00193
Ethanol Followed by Placebo0.00141

[back to top]

PK of Acetaldehyde: T1/2

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionhours (Mean)
1.0 mg/kg Antizol Followed by Ethanol3.14
Ethanol Followed by 1.0 mg/kg Antizol3.08
3.0 mg/kg Antizol Followed by Ethanol2.48
Ethanol Followed by 3.0 mg/kg Antizol1.72
5.0 mg/kg Antizol Followed by Ethanol3.45
Placebo Followed by Ethanol2.39
Ethanol Followed by Placebo2.09

[back to top]

PK of Acetaldehyde: Tmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionhours (Median)
1.0 mg/kg Antizol Followed by Ethanol0.500
Ethanol Followed by 1.0 mg/kg Antizol0.650
3.0 mg/kg Antizol Followed by Ethanol1.00
Ethanol Followed by 3.0 mg/kg Antizol1.33
5.0 mg/kg Antizol Followed by Ethanol0.500
Placebo Followed by Ethanol0.500
Ethanol Followed by Placebo0.925

[back to top]

PK of Ethanol: AUC(0-∞)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionmg*hr/mL (Mean)
1.0 mg/kg Antizol Followed by Ethanol245
Ethanol Followed by 1.0 mg/kg Antizol263
3.0 mg/kg Antizol Followed by Ethanol237
Ethanol Followed by 3.0 mg/kg Antizol215
5.0 mg/kg Antizol Followed by Ethanol271
Placebo Followed by Ethanol214
Ethanol Followed by Placebo198

[back to top]

PK of Ethanol: AUC(0-t)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionmg*hr/dL (Mean)
1.0 mg/kg Antizol Followed by Ethanol209
Ethanol Followed by 1.0 mg/kg Antizol209
3.0 mg/kg Antizol Followed by Ethanol205
Ethanol Followed by 3.0 mg/kg Antizol135
5.0 mg/kg Antizol Followed by Ethanol231
Placebo Followed by Ethanol157
Ethanol Followed by Placebo152

[back to top]

PK of Ethanol: AUC%Extrap

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionpercentage (Mean)
1.0 mg/kg Antizol Followed by Ethanol14.7
Ethanol Followed by 1.0 mg/kg Antizol20.5
3.0 mg/kg Antizol Followed by Ethanol13.2
Ethanol Followed by 3.0 mg/kg Antizol20.0
5.0 mg/kg Antizol Followed by Ethanol12.1
Placebo Followed by Ethanol13.4
Ethanol Followed by Placebo13.9

[back to top]

PK of Ethanol: CL/F

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventiondL/hr (Mean)
1.0 mg/kg Antizol Followed by Ethanol140
Ethanol Followed by 1.0 mg/kg Antizol138
3.0 mg/kg Antizol Followed by Ethanol142
Ethanol Followed by 3.0 mg/kg Antizol131
5.0 mg/kg Antizol Followed by Ethanol112
Placebo Followed by Ethanol159
Ethanol Followed by Placebo167

[back to top]

PK of Ethanol: Cmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionmg/dL (Mean)
1.0 mg/kg Antizol Followed by Ethanol62.7
Ethanol Followed by 1.0 mg/kg Antizol70.3
3.0 mg/kg Antizol Followed by Ethanol80.5
Ethanol Followed by 3.0 mg/kg Antizol43.3
5.0 mg/kg Antizol Followed by Ethanol74.9
Placebo Followed by Ethanol59.3
Ethanol Followed by Placebo55.1

[back to top]

PK of Ethanol: DN AUC(0-∞)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Intervention(mg*hr/dL)/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol0.00760
Ethanol Followed by 1.0 mg/kg Antizol0.00731
3.0 mg/kg Antizol Followed by Ethanol0.00705
Ethanol Followed by 3.0 mg/kg Antizol0.00768
5.0 mg/kg Antizol Followed by Ethanol0.00917
Placebo Followed by Ethanol0.00681
Ethanol Followed by Placebo0.00617

[back to top]

PK of Ethanol: DN AUC(0-t)

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Intervention(mg*hr/dL)/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol0.00648
Ethanol Followed by 1.0 mg/kg Antizol0.00585
3.0 mg/kg Antizol Followed by Ethanol0.00613
Ethanol Followed by 3.0 mg/kg Antizol0.00483
5.0 mg/kg Antizol Followed by Ethanol0.00791
Placebo Followed by Ethanol0.00508
Ethanol Followed by Placebo0.00476

[back to top]

PK of Ethanol: DN Cmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Intervention(mg/dL)/mg (Mean)
1.0 mg/kg Antizol Followed by Ethanol0.00195
Ethanol Followed by 1.0 mg/kg Antizol0.00198
3.0 mg/kg Antizol Followed by Ethanol0.00243
Ethanol Followed by 3.0 mg/kg Antizol0.00155
5.0 mg/kg Antizol Followed by Ethanol0.00261
Placebo Followed by Ethanol0.00193
Ethanol Followed by Placebo0.00175

[back to top]

PK of Ethanol: T1/2

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionhours (Mean)
1.0 mg/kg Antizol Followed by Ethanol1.51
Ethanol Followed by 1.0 mg/kg Antizol1.95
3.0 mg/kg Antizol Followed by Ethanol1.43
Ethanol Followed by 3.0 mg/kg Antizol1.78
5.0 mg/kg Antizol Followed by Ethanol1.67
Placebo Followed by Ethanol1.45
Ethanol Followed by Placebo1.32

[back to top]

PK of Ethanol: Tmax

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

Interventionhours (Median)
1.0 mg/kg Antizol Followed by Ethanol1.50
Ethanol Followed by 1.0 mg/kg Antizol0.833
3.0 mg/kg Antizol Followed by Ethanol0.500
Ethanol Followed by 3.0 mg/kg Antizol1.42
5.0 mg/kg Antizol Followed by Ethanol0.500
Placebo Followed by Ethanol0.500
Ethanol Followed by Placebo1.01

[back to top]

PK of Ethanol: Vz/F

(NCT00661141)
Timeframe: Days 1 and 2: prior to administration of 1st treatment (ethanol or study drug); 10, 20, and 30 min prior to administration of second treatment (study drug or ethanol); 40, 50, 60 min and 2, 3, 4, 5, 6, and 8 hr post administration of 1st treatment

InterventiondL (Mean)
1.0 mg/kg Antizol Followed by Ethanol297
Ethanol Followed by 1.0 mg/kg Antizol387
3.0 mg/kg Antizol Followed by Ethanol295
Ethanol Followed by 3.0 mg/kg Antizol330
5.0 mg/kg Antizol Followed by Ethanol242
Placebo Followed by Ethanol287
Ethanol Followed by Placebo321

[back to top]

Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation

AEs were collected to evaluate the safety and tolerability of oral Antizol with concomitant ethanol administration in particitpants with symptoms of acetaldehyde toxicity associated with altered ethanol metabolism. AE: any untoward medical event that occurs following the first administration of study medication until the study participant's last study visit, whether or not the event is considered drug related. SAE: an event that meets any of the following criteria: results in death; is life threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of an exposed subject; is medically significant or an important medical event as assessed by investigator or sponsor; is, in the opinion of the investigator, an important medical event. (NCT00661141)
Timeframe: Study Day 0 through Study Visit Day 7

,,,,
InterventionParticipants (Count of Participants)
Any AEMild AEModerate AESevere AELife-Threatening/Disabling AEDeathPossibly or Probably Related AEAE Leading to Study DiscontinuationSerious AE
Antizol 1.0 mg/kg131320001300
Antizol 3.0 mg/kg660000600
Antizol 5.0 mg/kg880000500
Overall282870002700
Pooled Placebo211950001800

[back to top]